Intralytix, Inc. announced that it has received a multimillion-dollar grant (AI 148054) from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), for the clinical development of its bacteriophage therapy […]
Today, Rebiotix and Ferring Pharmaceuticals announced positive preliminary findings from their ongoing pivotal Phase 3 trial of the investigational microbiome-based treatment, RBX2660. These preliminary positive efficacy findings mark an important milestone, advancing RBX2660 in its […]
The COVID-19 crisis is causing immense suffering and an appalling death toll. It has also dramatically impacted our personal and professional lives, and individuals, businesses and investors can’t wait to get back to normalcy. However, […]
Probiota is set with the ambition to connect business and science of the microbiome space, build community, start conversations and inspire innovation, as very well expressed by Nathan Gray from William Reed. Probiota this year […]
Although the April 15, 2020 decision of the U.S. Patent Trial and Appeal Board (PTAB) was to invalidate The University of Chicago’s US microbiome patent, much can be learned and some positive notes echo from […]
Chr. Hansen Holding A/S and HSO Health Care GmbH today entered into an agreement, under which Chr. Hansen will acquire HSO Health Care. The acquisition of the Austria-based B2B company specializing in probiotics for women’s […]
Taxonomy is the branch of science that classifies and names organisms. Lactobacillus were first described in 1901 with Lactobacillus delbrueckii, a species indispensable in yogurt, and grew exponentially since the beginning of the 21stcentury thanks to […]
Eastern Arc researchers at the University of East Anglia based in the Quadram Institute and the School of Biosciences at the University of Kent are working to help generate a vaccine against coronavirus and providing […]
Lodo Therapeutics Corp., a biotechnology company applying its proprietary platform to reinvent natural product drug discovery, today announced it has achieved a preclinical milestone in its multi-target strategic collaboration with Genentech, a member of the […]
OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announced today that it has completed enrollment in its Oxabact ePHex phase III study. Oxabact is an investigational […]
Gilead Sciences, Inc. (Nasdaq: GILD) and Second Genome, a leader in microbiome science, today announced that the companies have entered into a four-year strategic collaboration to identify biomarkers associated with clinical response in up to […]